Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (BIC-STaR)

Gilead Sciences

Status: Completed

Conditions: HIV-1-infection

Treatments: Drug: B/F/TAF

Study type: Observational

Funder types: Industry

Identifiers

NCT03580668

GS-CA-380-4574

Details and patient eligibility

About

The primary objective of this study is to evaluate HIV-1 RNA suppression, defined as HIV-1 RNA <50 copies/mL, at 12 months after initiating or switching to Bictegravir/ Emtricitabine/Tenofovir alafenamide (B/F/TAF).

Enrollment: 201 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HIV-1 infection
• Signed informed consent
• Initiating treatment with B/F/TAF in accordance with the product monograph

Exclusion criteria

Participation in any other observational or interventional clinical trial without prior approval from the Medical Monitor

Trial design

201 participants in 1 patient group

B/F/TAF

Description:

Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) therapy in HIV-1 infected adults who initiate B/F/TAF therapy

Treatment:

Drug: B/F/TAF